[翻译文章] 了解免疫媒介疾病患者的生物治疗方法. 在BIOINFO的研究中,
Carlos Seguí-Solanes1, Lidia Estrada2, Esther Ramírez Herráiz3
1Servicio de Farmacia, Hospital de Granollers, Granollers, Barcelona, Spain.
概括
患有免疫媒介性炎症疾病的患者对生物治疗有可接受的知识,但对生物类似药的理解有限. 风湿病患者在治疗前表现出更好的知识.
科学领域:
- 药理学和治疗学 药理学和治疗学
- 免疫学 免疫学 免疫学
- 患者教育 患者教育
背景情况:
- 生物疗法和生物仿制药对于管理免疫媒介炎症疾病 (IMIDs) 至关重要.
- 患者对这些复杂的治疗方法的理解对于坚持和有效管理至关重要.
- 关于患者知识的数据有限,特别是在门诊医疗保健机构内.
研究的目的:
- 评估患者对生物疗法和生物仿制药的知识水平.
- 确定影响IMID患者患者理解的因素.
- 在门诊药物护理单位开始生物治疗之前评估知识.
主要方法:
- 从2020年5月到2021年3月,进行了一项观察性,前性,多中心研究.
- 一项9个问题的调查评估了患者在开始生物治疗之前的知识.
- 169名患有IMID的患者被纳入分析.
主要成果:
- 平均患者知识分数为45分之29.4,其中64.5%达到可以接受的水平 (>27分).
- 与生物类似信息相比,患者对剂量和施用技术的知识更高.
- 由风湿病学服务管理的患者显示了统计学上显著的更高知识得分 (p<.05).
结论:
- 总体而言,患者对生物治疗的知识是可以接受的,尽管对生物类似药的理解需要改进.
- 有关生物相似特征和信息来源存在特定的知识差距.
- 风湿病治疗与患者对生物治疗的理解提高有关.
相关概念视频
Tumor Immunotherapy
491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491
Cytotoxic T Cells-mediated Immune Response
858
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
858
Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
119
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
119
Cell-mediated Immune Responses
67.8K
Overview
67.8K


